Unnati Pharmaceuticals Private Limited - Due diligence report

A 360° intelligence report on Unnati Pharmaceuticals Private Limited: trust score, financial health, credit view, compliance, directors, gro…

2003-06-24 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
Connect MCP
UP Unnati Pharmaceuticals Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Unnati Pharmaceuticals Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
84/100
Trust Score
Low Risk

Unnati Pharmaceuticals Private Limited is assessed as Low Risk with a Trust Score of 84/100. Unnati Pharmaceuticals Private Limited is an active private limited indian non-government company incorporated in 2003, operating in the Chemicals sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 14 Aug 2026 from the latest processed filings. Unnati Pharmaceuticals Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
84/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 3 open (12.88 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited3 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 5 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
NAISHIL HETAL MEHTA 01234567 Director 01/04/2018 6 yrs Approved
HETAL BHUPATRAI MEHTA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Operating for 23+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
3 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence83/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment61/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 12.88 cr already registered.
  • Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 1 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
04 Mar 2022
Charge created
Hdfc Bank Limited - 13.35 Lakh
12 Mar 2018
Charge created
Hdfc Bank Limited - 5.00 cr
30 Sep 2017
Director ceased
NAISHIL HETAL MEHTA
21 Dec 2016
Director appointed
NAISHIL HETAL MEHTA (Director)
Director ceased
RAHUL JITENDRA PAREKH
30 Nov 2011
Director ceased
KIRAN CHANDRAKANT SANGHAVI
31 Mar 2011
Securities allotted
3.00 Preference Shares - 300.00 raised
30 Jun 2010
Director appointed
HETAL BHUPATRAI MEHTA (Director)
10 Jun 2010
Securities allotted
1.00 Preference Shares - 100.00 raised
31 May 2009
Director ceased
KAUSHIK KANTILAL PAREKH
31 Mar 2009
Securities allotted
8500.00 Equity Shares - 8.50 Lakh raised
28 Feb 2008
Charge created
Hdfc Bank Limited - 7.75 cr
24 Jun 2003
Incorporated
Registered with Roc Mumbai
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
5 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
J L Morison U51109WB1934PLC088167 Saltlake, West Bengal, India
Netmatrix Crop Care Private Limited U72200TG2000PTC138537 Hyderabad, Telangana, India
Premier Adhesives Private Limited U24290GJ1998PTC135234 Vapi, Gujarat, India
Tiku Ram Gum And Chemicals Private Limited U24305HR2006PTC036199 Siwani Mandi, Haryana, India
Tojo Vikas International Private Limited U74899DL1999PTC099582 New Delhi, Delhi, India
Kunnathan Polymers Private Limited U24132KL2003PTC016714 Ernakulam, Kerala, India
Phygeno U74899DL1989PTC037758 New Delhi, Delhi, India
Catalysts Bio-Technologies Private Limited U24234DL2007PTC159686 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Unnati Pharmaceuticals Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Unnati Pharmaceuticals Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 70/100, margin trends, ownership structure and peer set for Unnati Pharmaceuticals Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 84/100, distress signals and MSME payment-delay disclosures - know whether Unnati Pharmaceuticals Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Unnati Pharmaceuticals Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Unnati Pharmaceuticals Private Limited an active company?

Unnati Pharmaceuticals Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Unnati Pharmaceuticals Private Limited financially healthy?

Unnati Pharmaceuticals Private Limited has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Unnati Pharmaceuticals Private Limited?

Its overall Trust Score is 84/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Unnati Pharmaceuticals Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Unnati Pharmaceuticals Private Limited have loans or charges against its assets?

3 open charge(s) are registered against its assets.

Is Unnati Pharmaceuticals Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Unnati Pharmaceuticals Private Limited?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.